Literature DB >> 12673165

Nuclear imaging is more sensitive for the detection of viable myocardium than dobutamine echocardiography.

G W Sloof1, F F Knapp, A van Lingen, J Eersels, D Poldermans, J J Bax.   

Abstract

Intact perfusion, preserved metabolism of free fatty acids and glucose, and the presence of contractile reserve have been used as markers of viable myocardium. However, not all viable myocardium may exhibit all these characteristics. Accordingly, these features were evaluated in patients with chronic coronary artery disease and left ventricular dysfunction. Fourteen patients with chronic ischaemic heart disease and depressed left ventricular function (LVEF 34+/-10%) perfusion was evaluated by early resting 201Tl single photon emission computed tomography (SPECT), fatty acid utilization by 15-p-[123I]iodophenyl-3-(R,S)-methylpentadecanoic acid SPECT, glucose utilization by 2-[18F]fluoro-2-deoxy-D-glucose SPECT and contractile reserve (CR) by dobutamine echocardiography. The comparison of the different modalities was restricted to akinetic or dyskinetic myocardium as assessed by resting 2-dimensional echocardiography. For all techniques a 13-segment model was used. Sixty-four of 182 segments (35%) showed akinesia or dyskinesia. Intact perfusion was found in 33/64 (52%) segments. Fatty acid utilization was maintained in 38/64 (59%) segments and glucose utilization was maintained in 38/64 (59%) segments. CR was present in significantly fewer segments: 21 of 64 (33%) (P<0.01 vs glucose and fatty acid utilization). In the 21 segments with preserved CR, perfusion was intact in 16/21 (76%) segments, fatty acid utilization in 19/21 (90%) segments and glucose utilization was preserved in all (100%) segments. Conversely, in the 43 segments without CR, 17 segments (40%) showed intact perfusion, 19 segments (44%) preserved fatty acid utilization and 17 (40%) still showed preserved glucose utilization. Disagreement in segments between the viability markers was caused mainly by segments without CR but preserved perfusion, fatty acid or glucose utilization. The substantial number of segments with preserved glucose and fatty acid utilization but without contractile reserve, suggests an underestimation of myocardial viability by dobutamine echocardiography.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12673165     DOI: 10.1097/00006231-200304000-00006

Source DB:  PubMed          Journal:  Nucl Med Commun        ISSN: 0143-3636            Impact factor:   1.690


  6 in total

1.  Viability assessment: nuclear imaging vs. dobutamine echocardiography.

Authors:  Jeroen J Bax; Ernst E van der Wall
Journal:  Int J Cardiovasc Imaging       Date:  2003-12       Impact factor: 2.357

Review 2.  Radionuclide techniques for the assessment of myocardial viability and hibernation.

Authors:  J J Bax; E E van der Wall; M Harbinson
Journal:  Heart       Date:  2004-08       Impact factor: 5.994

3.  Evaluation of hibernating myocardium.

Authors:  J J Bax; D Poldermans; E E van der Wall
Journal:  Heart       Date:  2004-11       Impact factor: 5.994

Review 4.  Imaging: guiding the clinical translation of cardiac stem cell therapy.

Authors:  Patricia K Nguyen; Feng Lan; Yongming Wang; Joseph C Wu
Journal:  Circ Res       Date:  2011-09-30       Impact factor: 17.367

Review 5.  Position Paper of the European Society of Cardiology Working Group Cellular Biology of the Heart: cell-based therapies for myocardial repair and regeneration in ischemic heart disease and heart failure.

Authors:  Rosalinda Madonna; Linda W Van Laake; Sean M Davidson; Felix B Engel; Derek J Hausenloy; Sandrine Lecour; Jonathan Leor; Cinzia Perrino; Rainer Schulz; Kirsti Ytrehus; Ulf Landmesser; Christine L Mummery; Stefan Janssens; James Willerson; Thomas Eschenhagen; Péter Ferdinandy; Joost P G Sluijter
Journal:  Eur Heart J       Date:  2016-04-07       Impact factor: 29.983

Review 6.  Pursuing meaningful end-points for stem cell therapy assessment in ischemic cardiac disease.

Authors:  Maria Dorobantu; Nicoleta-Monica Popa-Fotea; Mihaela Popa; Iulia Rusu; Miruna Mihaela Micheu
Journal:  World J Stem Cells       Date:  2017-12-26       Impact factor: 5.326

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.